Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts

BACKGROUND: Soft tissue sarcoma (STS) comprises a family of rare, heterogeneous tumors of mesenchymal origin. Single-agent doxorubicin remains the first-line standard-of-care treatment for advanced and inoperable STS, but response rates are only around 15%. In 2016, phase Ib/II clinical trial result...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornillie, Jasmien, Wozniak, Agnieszka, Van Renterghem, Britt, Van Winkel, Nathalie, Wellens, Jasmien, Gebreyohannes, Yemarshet K., Debiec-Rychter, Maria, Sciot, Raf, Hompes, Daphne, Schöffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647161/
https://www.ncbi.nlm.nih.gov/pubmed/31331295
http://dx.doi.org/10.1186/s12885-019-5872-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647161/
https://www.ncbi.nlm.nih.gov/pubmed/31331295
http://dx.doi.org/10.1186/s12885-019-5872-1

Ejemplares similares